GW Pharma and New York State to initiate trials of cannabidiol in epilepsy

UK-based GW Pharmaceuticals (Nasdaq: GWPH), a biopharmaceutical company focused on developing novel therapeutics from its proprietary cannabinoid product platform, has welcomed an agreement with New York State to initiate clinical trials using cannabidiol (CBD) to help treat children diagnosed with epilepsy who suffer from seizures and other medical complications.

New York State Governor Andrew Cuomo announced that New York will be the second state in the USA to initiate trials for cannabidiol for children whose medical conditions have not been successfully treated by other methods.

“No child should be forced to live with the heart-breaking effects of medication-resistant epilepsy," Governor Cuomo said. "Young New Yorkers battling these diseases deserve treatments that work for them, and by investigating the merits of cannabidiol we are pushing the boundaries of modern medicine and working to fundamentally improve the quality of life for those children. I am very hopeful that this research collaboration will grow our understanding of these types of medications and ultimately help New Yorkers lead better lives."